PLX-PAD
- Generic Name
- PLX-PAD
- Drug Type
- Biotech
- Unique Ingredient Identifier
- DPX6XLD4X1
Expanded Access Treatment of Subjects With Critical Limb Ischemia (CLI) With Minor Tissue Loss Who Are Unsuitable for Revascularization
- Conditions
- Critical Limb Ischemia (CLI)
- First Posted Date
- 2019-03-22
- Last Posted Date
- 2020-07-28
- Lead Sponsor
- Pluristem Ltd.
- Registration Number
- NCT03886506
- Locations
- 🇺🇸
OBL-NJ Endovascular & Amputation Prevention, LLC,1429 Broad St., Clifton, NJ, Clifton, New Jersey, United States
🇺🇸Holy Name Medical Center,718 Teaneck Road, Teaneck, New Jersey, United States
Treatment of Muscle Injury Following Arthroplasty for Hip Fracture (HF)
- First Posted Date
- 2018-03-02
- Last Posted Date
- 2023-09-28
- Lead Sponsor
- Pluristem Ltd.
- Target Recruit Count
- 240
- Registration Number
- NCT03451916
- Locations
- 🇧🇬
MHAT "Serdika" Department of Orthopedy and Traumatology, Sofia, Bulgaria
🇧🇬Military Medical Academy, Sofia, Bulgaria
🇧🇬Specialized Hospital for Active Treatment in Orthopedy, Sofia, Bulgaria
Safety Study of PLX-PAD Cells to Treat Pulmonary Arterial Hypertension (PAH)
- First Posted Date
- 2013-02-21
- Last Posted Date
- 2016-02-17
- Lead Sponsor
- United Therapeutics
- Target Recruit Count
- 6
- Registration Number
- NCT01795950
- Locations
- 🇦🇺
The Prince Charles Hospital, Brisbane, Queensland, Australia
🇦🇺The Alfred Hospital, Melbourne, Australia
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath